We serve Chemical Name:1-Cbz-3-carbamoylpiperidine CAS:569348-14-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-Cbz-3-carbamoylpiperidine
CAS.NO:569348-14-7
Synonyms:benzyl 3-carbamoylpiperidine-1-carboxylate
Molecular Formula:C14H18N2O3
Molecular Weight:262.30400
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:475.5ºC at 760 mmHg
Density:1.224 g/cm3
Index of Refraction:1.568
PSA:72.63000
Exact Mass:262.13200
LogP:2.15870
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like benzyl 3-carbamoylpiperidine-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzyl 3-carbamoylpiperidine-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,benzyl 3-carbamoylpiperidine-1-carboxylate Use and application,benzyl 3-carbamoylpiperidine-1-carboxylate technical grade,usp/ep/jp grade.
Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-Cbz-3-carbamoylpiperidine manufacturer The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. 1-Cbz-3-carbamoylpiperidine supplier Health officials said it remained unclear where he had developed the disease. 1-Cbz-3-carbamoylpiperidine vendor The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-Cbz-3-carbamoylpiperidine factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.
